Trusted by:
Dr. Ho Sang Jung and his research team from the Advanced Bio and Healthcare Materials Research Division at the Korea Institute of Materials Science (KIMS), in collaboration with Seoul St. Mary’s Hospital, have developed a technology that enables the diagnosis of osteoarthritis and rheumatoid arthritis within 10 minutes using synovial fluid.
Artificial intelligence models, pretrained on vast datasets, significantly outperformed a standard baseline model in identifying nonmelanoma skin cancers (NMSC) from digital images of tissue samples, according to research presented at the American Association for Cancer Research (AACR) Annual Meeting, held April 25-30.
Study raises the question of whether social ‘hippie’ spiders truly have personalities at all Individual behaviour in spider communities far more fluid than previously thought Instead of fixed behavioural types, spiders appear to adjust their behaviour dynamically based on circumstances
• RO7589831, a new drug from Roche, is first in a new class of drugs called Werner helicase inhibitors • Drug works similarly to other DNA damage repair inhibitors, such as PARP inhibitors • This class of drugs is important because many solid tumor patients with microsatellite instability (MSI) do not benefit from currently approved immunotherapies • Encouraging early results in this first-in-human trial prompted additional trial cohorts to optimize recommended dose for future clinical development
· LUT014, a topical BRAF inhibitor made by Lutris Pharma, is the first agent to treat the cause of the rash without interfering with the treatment itself · Over two-thirds of patients had successful treatment with the higher dose of LUT014 compared to one-third with placebo
UCLA researchers demonstrated that a novel topical BRAF inhibitor gel called LUT014 significantly reduces the severity of an acne-like rash, a common and painful side effect experienced by patients undergoing anti-EGFR therapies for colorectal cancer.
20240208171546.png&width=400&height=400)
New results from a clinical trial led by Memorial Sloan Kettering Cancer Center (MSK), demonstrate how immunotherapy alone can allow people with MMRd cancers to avoid surgery and preserve their quality of life. The results, presented at the 2025 American Association of Cancer Research (AACR) Annual Meeting and published simultaneously in The New England Journal of Medicine (NEJM), found that 80 percent of patients did not require surgery, radiation, or chemotherapy after six months of treatment with immunotherapy alone.
• Combining Lynparza (olaparib) and Keytruda (pembrolizumab) showed antitumor activity in multiple cancer types, particularly those with BRCA1/2 mutations • Combination demonstrated complete responses and partial responses in different cancer types, including those beyond the currently approved indications for these therapies
A new study from researchers at Moffitt Cancer Center shows that blocking a chemical process called nitrosylation could make one of the most aggressive forms of melanoma more treatable.
An international phase 3 clinical trial led by Washington University School of Medicine in St. Louis and Dana-Farber Brigham Cancer Center shows that patients with certain locally advanced head and neck cancers benefited from the addition of the immunotherapy drug pembrolizumab (brand name Keytruda) to standard-of-care therapy. Patients who received pembrolizumab saw greater tumor shrinkage prior to surgery and, on average, survived cancer-free almost two years longer than did patients who only received standard-of-care therapy.
RSS
Medicine keyboard_arrow_right
Sciencekeyboard_arrow_right
Life keyboard_arrow_right
Business keyboard_arrow_right
Journal News keyboard_arrow_right
By Location keyboard_arrow_right
Meetings, Grants, and Events keyboard_arrow_right